mechanism of action – mycolab.ai

If psychedelics heal, how do they do it?

mycolabadmin

Psychedelic drugs like MDMA and magic mushrooms are showing remarkable promise in treating serious mental health conditions like PTSD and depression, with clinical trials demonstrating higher success rates than traditional therapy alone. However, scientists still don’t fully understand how these drugs work at the molecular and brain level, or whether the hallucinations they produce are necessary for healing. Researchers are investigating whether modified versions without hallucinations could provide the same benefits while being easier to administer, while also exploring how individual factors and treatment environment affect outcomes.

Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential

mycolabadmin

Psychedelic drugs like LSD and psilocybin are substances that alter perception and consciousness. Research shows they may help treat serious mental health conditions including depression, anxiety, and PTSD by affecting how the brain forms new connections. These substances are relatively safe compared to many legal drugs, and scientists believe they could revolutionize mental health treatment when used properly under medical supervision.

Psilocin, A Psychedelic Drug, Exerts Anticonvulsant Effects Against PTZ- and MES-Induced Seizures in Mice via 5-HT1A and CB1 Receptors: Involvement of Nitrergic, Opioidergic, and Kynurenine Pathways

mycolabadmin

Researchers tested psilocin, the active ingredient in magic mushrooms, and found it could reduce seizures in mice at low doses (3-5 mg/kg) without causing psychedelic effects. The anticonvulsant benefits were mediated through several brain pathways including serotonin, cannabinoid, opioid, and nitric oxide signaling systems. The effects persisted for at least 9 days after a single dose, suggesting psilocin may have potential as a new treatment for epilepsy, though human clinical trials are needed to confirm these findings.

Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome

mycolabadmin

This study examined whether the psychological experiences people have while taking ketamine or psilocybin—such as feeling disconnected or having spiritual insights—are actually responsible for their mental health improvements. Researchers analyzed 23 studies and found that these subjective experiences explain about 10% of ketamine’s benefits and 24% of psilocybin’s benefits. Psilocybin’s effects appear more connected to therapeutic outcomes than ketamine’s, and both drugs showed stronger connections between subjective effects and treatment success in substance use disorder compared to depression.

Fungal Drug Discovery for Chronic Disease: History, New Discoveries and New Approaches

mycolabadmin

This article examines how fungi have provided humanity with some of the most important medicines ever created, including penicillin, drugs that prevent organ rejection, and cholesterol-lowering statins. Many of these fungal compounds work as medicines because they target processes that are similar in both fungi and humans, helping them survive competition with other fungi while coincidentally treating human diseases. New researchers are now using modern genetic tools to discover additional fungal medicines, with several promising candidates currently being tested in clinical trials for cancer, depression, and other chronic diseases.

Isolation Techniques, Structural Characteristics, and Pharmacological Effects of Phellinus Polysaccharides: A Review

mycolabadmin

This review examines how scientists extract and study beneficial compounds called polysaccharides from a medicinal fungus called Phellinus. These polysaccharides show promise in fighting cancer, reducing inflammation, and boosting immune function. Different extraction methods affect the quality and effectiveness of these compounds, and researchers are working to optimize these techniques for better therapeutic applications.

Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review

mycolabadmin

This review examines how psilocybin, the active compound in magic mushrooms, may help treat difficult-to-treat conditions like smoking addiction, alcohol dependence, and depression. Clinical trials show psilocybin-assisted therapy achieves better smoking cessation rates (80%) than standard medications and reduces depression symptoms as effectively as common antidepressants. The treatment works differently than daily medications, requiring only a few supervised doses weeks apart, potentially offering a new option for millions of people.

Exploring the health benefits of Ganoderma: antimicrobial properties and mechanisms of action

mycolabadmin

Ganoderma is a medicinal mushroom that has been used in traditional medicine for thousands of years and is now being studied for its ability to fight infections. The mushroom contains special compounds like polysaccharides and triterpenoids that can kill harmful bacteria and fungi in multiple ways—by breaking down their cell walls, stopping them from reproducing, and boosting your immune system. Scientists have found that Ganoderma works against many dangerous bacteria including antibiotic-resistant strains, and it may offer a natural alternative to conventional antibiotics as antibiotic resistance becomes a major global health problem.

Recent innovations and challenges in the treatment of fungal infections

mycolabadmin

Fungal infections are becoming more common and dangerous, especially for people with weakened immune systems, and many fungi are developing resistance to current medications. Doctors and researchers are developing new treatment strategies, including combining multiple drugs together and using advanced technologies to deliver medicines more effectively to infected areas. Natural compounds from plants and new biotechnology tools like genetic engineering and nanoparticles show promising results for fighting drug-resistant fungal infections.

Sandalwood Sesquiterpene (Z)-α-Santalol Exhibits In Vivo Efficacy Against Madurella mycetomatis in Galleria mellonella Larvae

mycolabadmin

Researchers tested sandalwood oil components against a fungal disease called eumycetoma that causes serious skin infections, especially in tropical regions. They found that one component called (Z)-α-santalol was highly effective at killing the fungus and extending survival in laboratory-infected moth larvae, while actually being relatively safe. This natural compound shows promise as a potential new treatment for this neglected disease that currently relies on expensive drugs that are only 40% effective.

Research Keyword: mechanism of action